In this episode of Kidney Commute: Pitstop, we explore key insights from the KDIGO Commentary on the 2025 KDOQI Clinical Practice Guideline for autosomal dominant polycystic kidney disease (ADPKD). Host Anna Gaddy is joined by Dr. Neera Dahl and Dr. Terry Watnick to discuss how the updated recommendations differ from prior guidance and what they mean for real world practice in the United States. The conversation highlights advances in genetic testing, practical considerations for implementing tolvaptan therapy, and emerging therapies on the horizon. Tune in for actionable takeaways to support clinical decision making and improve care for patients with ADPKD.

Access the commentary here: https://www.ajkd.org/article/S0272-6386(26)00003-X/fulltext